Mitochondrial DNA damage evident before Parkinson’s: Study
People with REM sleep behavior disorder, a condition that often precedes Parkinson’s disease, frequently have mitochondrial DNA (mtDNA) damage,…
Articles by Marisa Wexler, MS
Fecal microbiota transplant eases Parkinson’s symptoms in trial
Fecal microbiota transplant, a procedure that works to replace a person’s gut bacteria with gut bacteria from a healthy donor,…
Developer launches long-awaited study of light device for Parkinson’s
After years of delays, medical device company Photopharmics has started a pivotal clinical trial to test its Celeste device,…
Irlab moving on Phase 3 trial of mesdopetam to treat dyskinesia
Irlab Therapeutics is preparing to start a Phase 3 clinical trial of mesdopetam, its experimental oral treatment intending…
AI system uses home videos to aid in Parkinson’s diagnosis
A new system that uses artificial intelligence (AI) to analyze videos of people walking may help speed the diagnosis of…
Study supports using video games for Parkinson’s physical therapy
Playing rehabilitative video games along with physical therapy is more effective than conventional physical therapy only for managing symptoms of…
NLRP3 inhibitor VTX3232 heads to Phase 2a Parkinson’s clinical trial
Ventyx Biosciences plans to launch a Phase 2a clinical trial testing VTX3232, an oral medication designed to reduce inflammation…
Parkinson’s vaccine seen to target toxic alpha-synuclein in Phase 1 trial
Treatment with UB-312, a vaccine designed to trigger an immune response against toxic clumps of the alpha-synuclein protein, reduced these…
Cell, mouse models of Parkinson’s disease give data on GT-02287
By activating an enzyme known as beta-glucocerebrosidase, or GCase, the experimental therapy GT-02287 is able to improve nerve survival…
Phase 1 trial of therapy for GBA1 Parkinson’s advances in dosing
Dosing has begun in the second part of a Phase 1 clinical trial of GT-02287, an experimental oral therapy that…